🇺🇸 영어 원문
Osteoporosis, a condition that weakens bones and increases the risk of fractures, affects millions of people and remains a major challenge for doctors seeking safe treatments that can be used over long periods. In Germany alone, about six million people are affected, most of them women.
Because existing therapies can have limitations and side effects, researchers are looking for new biological targets that could lead to more effective ways of preserving or rebuilding bone. Scientists at Leipzig University have now identified one such target in GPR133, a receptor that appears to play an important role in keeping bones strong.
GPR133 belongs to a group known as adhesion G protein-coupled receptors. These receptors sit on the surface of cells and help them respond to signals from their surroundings. Although this family of receptors is still not fully understood, the new findings suggest GPR133 is closely involved in the processes that build and maintain healthy bone.
"If this receptor is impaired by genetic changes, mice show signs of loss of bone density at an early age – similar to osteoporosis in humans. Using the substance AP503, which was only recently identified via a computer-assisted screen as a stimulator of GPR133, we were able to significantly increase bone strength in both healthy and osteoporotic mice," explains Professor Ines Liebscher, lead investigator of the study from the Rudolf Schönheimer Institute of Biochemistry at the Faculty of Medicine.
The results point to GPR133 as a potentially valuable target for future osteoporosis treatments. The researchers found that stimulating the receptor with AP503 increased bone strength not only in healthy mice, but also in mice with osteoporosis-like bone loss.
Inside bone tissue, GPR133 responds to physical forces and interactions between nearby bone cells. When the receptor is activated, it sets off signaling that changes the balance between the cells that build bone and those that break it down.
Bone-forming cells (osteoblasts) are responsible for producing new bone tissue. Bone-resorbing cells (osteoclasts), by contrast, remove old bone as part of the skeleton’s normal cycle of renewal. Healthy bones depend on maintaining the right balance between these two processes.
Activation of GPR133 encourages the activity of osteoblasts while reducing the activity of osteoclasts. This shifts the balance toward stronger and more durable bone.
AP503 appears to imitate the natural process that activates GPR133. That raises the possibility that the compound could eventually be used to increase bone strength or help restore bone that has already been weakened. One potential application would be osteoporosis associated with menopause, when declining hormone levels can accelerate bone loss in women.
The findings could have broader implications because AP503 may affect more than the skeleton.
In an earlier study, researchers at Leipzig University had already found that activation with AP503 also strengthens skeletal muscle.
"The newly demonstrated parallel strengthening of bone once again highlights the great potential this receptor holds for medical applications in an aging population," says Dr. Juliane Lehmann, lead author of the study and a researcher at the Rudolf Schönheimer Institute of Biochemistry.
A treatment capable of improving both bone and muscle strength could be especially relevant for older adults.
🇰🇷 한국어 요약
안녕하세요, 여러분! 이번 기사에서는 뼈를 튼튼하게 만드는 새로운 ‘스위치’에 대한 이야기를 해 볼게요. 골다공증은 뼈가 약해지고 골절 위험이 커지는 질환으로, 전 세계 수백만 명이 영향을 받고 있으며 독일에서만 약 600만 명, 특히 여성이 많다고 합니다. 기존의 치료법은 부작용이나 한계가 있을 수 있기 때문에 연구자들은 새로운 치료 표적을 찾고 있었어요. 독일 라이프치히 대학교 연구팀은 GPR133이라는 수용체가 뼈 건강에서 중요한 역할을 하는 것을 발견했습니다. GPR133은 세포 표면에서 주변 신호에 반응하는 수용체 집단에 속하는데, 유전적 변화로 기능이 떨어지면 쥐에서 젊은 나이에 뼈 밀도가 줄어드는 증상이 나타난다고 해요. 연구진은 컴퓨터 스크리닝으로 찾아낸 물질 AP503이 GPR133을 자극한다는 사실을 이용해 건강한 쥐와 골다공증 상태의 쥐 모두에서 뼈 강도를 크게 높일 수 있었습니다. GPR133이 활성화되면 뼈를 만드는 골형성세포(osteoblast)의 활동은 늘리고, 뼈를 분해하는 골흡수세포(osteoclast)의 활동은 줄여서 뼈의 균형을 튼튼한 쪽으로 바꿔준다고 합니다. AP503은 이런 자연스러운 활성화 과정을 흉내 내는 것처럼 보이며, 폐경 후 호르몬 변화로 뼈가 약해지는 여성들에게도 도움이 될 수 있는 치료제가 될 가능성이 있습니다. 더 흥미로운 점은 이전 연구에서 AP503이 골격근도 강화한 것으로 확인되었다는 거예요. 뼈와 근육 모두를 튼튼하게 해 줄 수 있는 치료법은 고령화 사회에서 특히 중요할 수 있겠습니다. 다만 이 연구는 아직 쥐 실험 단계이고, 사람에게 바로 사용되기까지는 추가 연구가 필요하다는 점도 기억해 두세요.
🔑 핵심 단어 (Vocabulary)
- osteoporosis – 골다공증 – Osteoporosis, a condition that weakens bones and increases the risk of fractures.
- fracture – 골절 – a condition that weakens bones and increases the risk of fractures
- receptor – 수용체 – a receptor that appears to play an important role in keeping bones strong
- adhesion – 부착, 접착 – GPR133 belongs to a group known as adhesion G protein-coupled receptors.
- stimulator – 자극제 – the substance AP503, which was only recently identified via a computer-assisted screen as a stimulator of GPR133
- density – 밀도 – mice show signs of loss of bone density at an early age
- osteoblasts – 골형성세포 – Bone-forming cells (osteoblasts) are responsible for producing new bone tissue.
- osteoclasts – 골흡수세포 – Bone-resorbing cells (osteoclasts), by contrast, remove old bone as part of the skeleton’s normal cycle of renewal.
- durable – 튼튼한, 오래 견디는 – This shifts the balance toward stronger and more durable bone.
- implications – 함의, 파급 효과 – The findings could have broader implications because AP503 may affect more than the skeleton.
🔗 원문 링크
https://www.sciencedaily.com/releases/2026/09/260909005305.htm